WASHINGTON (Legal Newsline) – The Federal Trade Commission
(FTC) approved a final order that settles charges against Lupin that alleged its proposed $850 million acquisition of Gavis would be anticompetitive.
To complete the acquisition, the companies must divest
certain products. This includes generic doxycycline monohydrate capsules, which
treat bacterial infections, and generic mesalamine extended release capsules,
which treat ulcerative colitis.
Without this divestiture mandated by the FTC, the merger
would have combined two of only four companies that market the doxycycline
monohydrate capsules and eliminated one of only a few companies likely to enter
the generic mesalamine extended release capsule market.
The FTC voted 3-0 to approve the final order.